Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BP-007
- Development stage
- Preclinical
- Lead developer
- Brillian Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BP-007 is a pediatric, extended-release (ER) oral formulation of an existing antibiotic, developed by Brillian Pharma. The product utilizes Brillian's proprietary 'Unidose' technology, which presents the medication as a lyophilized suspension designed for single-dose administration. This delivery format is specifically engineered to improve dosing accuracy and patient compliance in children by providing a child-friendly, sustained-release alternative to traditional antibiotic dosing schedules. While the specific active pharmaceutical ingredient has not been disclosed, BP-007 is categorized within the company's pipeline as both an antibiotic and an extended-release formulation.
Beyond the preview
Go deeper on BP-007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BP-007.